2E9 Stock Chart & Stats
€0.08
<€0.01(11.11%)
At close: 4:00 PM EDT
€0.08
<€0.01(11.11%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€28.31M
Enterprise Value€317.65M
Total Cash (Recent Filing)€127.64M
Total Debt (Recent Filing)€866.00K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 12, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.92M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA near-zero debt-to-equity ratio reduces exposure to interest costs, refinancing pressure, and creditor claims while the company funds development. This conservative capital structure provides greater flexibility to manage volatility and pursue commercialization without the immediate constraints of heavy borrowing.
Substantial Equity BaseA substantial equity position can provide Intervacc with more time to develop and commercialize its veterinary vaccine platform before financial resources become critically constrained. That runway is strategically valuable in biotechnology, where regulatory and market adoption processes can take time.
Established Canine Vaccine CommercializationIntervacc already has a commercialized canine vaccine rather than relying solely on an early-stage pipeline. Existing product availability creates a foundation for veterinary-clinic and distributor adoption, while future market uptake and geographic expansion could build on an established commercial base.
Bears Say
Persistent UnprofitabilityNegative gross profit and large operating losses indicate that the current commercial model is not yet covering its operating and product costs. Continued losses weaken internal funding capacity, increase dependence on the equity base, and make a durable path to profitability an unresolved business issue.
Ongoing Cash BurnPersistent negative operating and free cash flow means Intervacc is consuming rather than generating cash through its operations. Even with low leverage, ongoing burn can require additional funding over time, potentially limiting investment choices and creating dilution pressure if profitability does not improve.
Weak Recent Revenue TrendThe latest trailing-twelve-month revenue decline suggests that earlier expansion has not yet translated into a consistently growing commercial trajectory. A weaker top line can reduce operating leverage, make fixed development and commercialization costs harder to absorb, and delay the route to positive margins.
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €28.31M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Nov 12, 2026 which is in 36 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on Aug 20, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of -€0.004 by >-€0.001.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.005 in its last earnings report, missing expectations of -€0.004. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
ExpreS2ion Biotech Holding AB
―
Immunicum AB
―
Cantargia AB
―